Prognosis
Covid Shot Supply Strains Are Set to Ease, Lawmakers Are Told
- Moderna says FDA gave positive feedback on dosing switch
- Changes at multiple companies could boost U.S. inventories
This article is for subscribers only.
Bottlenecks that have shadowed the U.S. immunization campaign could soon begin to ease, vaccine makers said in an online Capitol Hill hearing.
Moderna Inc. said it has received positive feedback from U.S. regulators on a proposal to expand the number of doses of its Covid-19 vaccine in each vial, while Pfizer Inc. said it expects its output to ramp up in coming weeks. And Johnson & Johnson, which could gain clearance for its one-shot vaccine as soon as this week, said it will be ready to ship millions of doses.